Shi, J., Sun, J., Liu, C., Chai, Z., Wang, N., Zhang, H., & Cheng, S. (2019). All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: Study protocol for a randomized controlled trial. Current controlled trials in cardiovascular medicine, 20(1), 245-9. https://doi.org/10.1186/s13063-019-3349-9
Citácia podle Chicago (17th ed.)Shi, Jie, Juxian Sun, Chang Liu, Zongtao Chai, Nanya Wang, Hui Zhang, a Shuqun Cheng. "All-trans-retinoic Acid (ATRA) Plus Oxaliplatin Plus 5-fluorouracil/leucovorin (FOLFOX) Versus FOLFOX Alone as Palliative Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Extrahepatic Metastasis: Study Protocol for a Randomized Controlled Trial." Current Controlled Trials in Cardiovascular Medicine 20, no. 1 (2019): 245-9. https://doi.org/10.1186/s13063-019-3349-9.
Citácia podľa MLA (8th ed.)Shi, Jie, et al. "All-trans-retinoic Acid (ATRA) Plus Oxaliplatin Plus 5-fluorouracil/leucovorin (FOLFOX) Versus FOLFOX Alone as Palliative Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Extrahepatic Metastasis: Study Protocol for a Randomized Controlled Trial." Current Controlled Trials in Cardiovascular Medicine, vol. 20, no. 1, 2019, pp. 245-9, https://doi.org/10.1186/s13063-019-3349-9.